MS = multiple sclerosis EDSS Expanded Disability Status Scale Descriptive data on the SPPB and measures of lower and upper extremity function are presented in Table 2.
The utility of these markers is not limited to hypoxic-ischemic injury, as we also observed immunoreactivity in active acute multiple sclerosis lesions (data not shown).
The overall similarity in adverse events between the three arms of the study, including serious events, is reassuring and consistent with previous studies of atacicept in rheumatoid arthritis, although the rate of total infections and serious infections was slightly higher with atacicept 150 mg, as observed in the rheumatoid arthritis 19 and multiple sclerosis studies unpublished data).
To determine the effectiveness of functional electrical stimulation (FES) on drop foot in patients with multiple sclerosis (MS), using data from standard clinical practice.
To systematically review reports of fingolimod persistence in the treatment of relapsing-remitting multiple sclerosis (RRMS) across data sources and practice settings, and to develop a consensus estimate of the 1-year real-world persistence rate.
The Swedish Multiple Sclerosis Registry contained data on 11 949 patients with recorded dates of onset.
Multiple sclerosis (MS) registry data, primarily from Europe, suggest that treatment with natalizumab delays time to relapse compared with platform therapy (interferon beta/glatiramer acetate).
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2288/11/80/prepub The authors are grateful to the pharmaceutical company for providing the multiple sclerosis clinical trial data.
Of the 284 remaining children, 2 with a history of epilepsy, 1 with a history of head trauma requiring surgery, 1 with a history of meningitis associated with coma, and 1 with multiple sclerosis were excluded after data collection.
We generated a multiple sclerosis month of birth data set using records from the database we previously established through our UK nationwide effort to recruit patients for genetic studies.
